Novel Rx

First, a quick recap of how we got here. Guselkumab, an IL-23p19-subunit inhibitor, was approved for moderate to severe plaque psoriasis in July 2017. With the success of DISCOVER 1 (D1) and…

The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a…

In rheumatoid arthritis we have a wide range of options available to us when we progress to a biologic treatment option. We have little to differentiate between these agents based on the clinical…

Giant cell arteritis (GCA) is associated with significant treatment related morbidity due to the dependence on glucocorticoids as a treatment option. We will hopefully see an impact on this due to…

Dr. Cush reviews the news, and kicks off ACR21 learning and how to take in the annual meeting. Study 144 pts Rx w/ Rituximab for Autoimmune renal Dz (AAV, FSGS, IgG4RD, LN, etc). 17% had Severe…

The pharmaceutical companies will feature the results of their pivotal clinical trials and data analyses at ACR Convergence 2021.  Below is a listing of some of their best studies for you to…

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like…